Truist raises target for SI-BONE stock from USD 23.00 to USD 25.00
Truist Securities has raised its price target for SI-BONE (SIBN) stock from USD 23.00 to USD 25.00, maintaining a Buy rating. This adjustment follows SI-BONE's strong second-quarter 2026 revenue and an increased full-year sales guidance for 2026 to USD 231.00-233.00 million. The company is set to report its third-quarter 2026 results on November 2, 2026.
SI-BONE To Report Third Quarter 2026 Financial Results on November 2, 2026
SI-BONE, Inc. (NASDAQ: SIBN) announced it will release its third-quarter 2026 financial results after market close on Monday, November 2, 2026. The company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time for investors to discuss the results. Live audio of the webcast will be accessible on SI-BONE's investor relations website.
SI-BONE To Report Third Quarter 2026 Financial Results on November 2, 2026
SI-BONE, Inc. announced it will release its financial results for the third quarter of 2026 after the market closes on Monday, November 2, 2026. The company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time, and a live audio webcast will be accessible through its investor relations website. SI-BONE specializes in developing procedural solutions for clinical challenges related to compromised bone.
SI-BONE stock has estimated November 9, 2026 earnings date
SI-BONE (SIBN) is estimated to report its third-quarter 2026 earnings on November 9, 2026, after market close, with a conference call scheduled for 4:30 p.m. ET. The company, which specializes in minimally invasive products for sacropelvic disorders, had a market capitalization of USD 882.0 million as of October 16, 2026. Analysts expect revenue of USD 55.27 million and adjusted EPS of minus USD 0.13 for the third quarter.
SI-BONE Price Target Raised to $25.00/Share From $23.00 by Truist Securities
Truist Securities has increased its price target for SI-BONE (NASDAQ:SIBN) shares to $25.00, up from the previous $23.00. The firm maintained a "buy" rating on the stock, indicating continued confidence in the company's prospects. SI-BONE's shares recently opened at $20.25 on Tuesday.
Truist lifts target for SI-BONE stock to USD 25.00
Truist has raised its price target for SI-BONE (SIBN) stock to $25.00 from $23.00, following the company's second-quarter 2026 revenue of $56.01 million. The stock was trading at EUR 17.65 on October 15, 2026, on Nasdaq, up 2.04 percent, with its next earnings report expected on November 9, 2026. This new target is 25.80 percent above SI-BONE's Nasdaq price of $19.87 on the same date.
Form 4 Si-Bone Inc: Laura Francis (Director, CEO) For: 12 October
This article reports on a Form 4 filing for Si-Bone Inc, detailing transactions made by Laura Francis, who serves as both a Director and CEO of the company. The filing pertains to activities on October 12th. The article is a brief notification without further details on the specific transactions.
How Si-bone Inc. (SIBN) Affects Rotational Strategy Timing
Si-bone Inc. (NASDAQ: SIBN) shows prevailing positive sentiment across near and mid-term horizons, potentially extending to the long term. The analysis indicates a mid-channel oscillation pattern and highlights an exceptional short setup with a 50.8:1 risk-reward ratio targeting a 15.1% downside. AI models have generated distinct trading strategies including position trading, momentum breakout, and risk hedging, with specific entry, target, and stop-loss zones.
A Francis trust lists $736K in SI-BONE (SIBN) shares for sale through Morgan Stanley Smith Barney.
A trust associated with David and Laura Francis is selling 38,006 common shares of SI-BONE, Inc. (SIBN) with an aggregate market value of $736,176.22 through Morgan Stanley Smith Barney. These shares were acquired from restricted stock unit vesting between May 2021 and November 2025. The Form 144 filing also notes previous sales by the trust and Laura Francis.
SI-BONE Insiders Sold US$4.2m Of Shares Suggesting Hesitancy
The article discusses SI-BONE's insider selling activity, highlighting that insiders have sold US$4.2 million worth of shares over the last year, with no recent purchases. This selling, especially at prices significantly above the current share price, might signal a lack of confidence in future growth despite the company's strong performance, raising questions for potential investors.
Form 4 Si-Bone Inc For: 11 October By Investing.com
This article from Investing.com reports on a Form 4 filing for Si-Bone Inc. dated October 11. It's a concise financial update for the company, indicating the date of the filing. The article does not contain further details about the Form 4 content beyond this basic notification.
Si-Bone director Jeffrey Dunn sells $369,400 in stock
Jeffrey W. Dunn, a director at SI-BONE, Inc., sold 20,000 shares of common stock worth $369,400 on October 1, 2026, through a pre-arranged trading plan. This sale occurred after the stock surged over 50% in six months, though analysis suggests it's overvalued. Dunn also acquired 20,000 shares via stock options on the same day.
Si-Bone director Jeffrey Dunn sells $369,400 in stock By Investing.com
Jeffrey W. Dunn, a director at SI-BONE, Inc. (NASDAQ:SIBN), sold 20,000 shares of common stock for $369,400 on October 1, 2026, under a pre-arranged trading plan, while also acquiring 20,000 shares through stock options. This transaction occurred after SI-BONE stock surged over 50% in six months, though analysis suggests it's currently overvalued. The company recently reported strong Q2 2026 results, beating Wall Street expectations for both earnings and revenue, leading to raised guidance and a reiterated Buy rating from Canaccord Genuity.
Si-Bone COO & CFO Anshul Maheshwari sells $94,078 in company stock
Si-Bone's COO & CFO, Anshul Maheshwari, sold 5,049 shares of company stock totaling approximately $94,078 in early October 2026. These transactions included "sell to cover" sales for tax obligations and a sale under a 10b5-1 trading plan. Despite the stock trading above its Fair Value, the company recently surpassed Q2 2026 revenue and earnings expectations, with strong analyst ratings maintained.
Form 4 Si-Bone Inc For: 11 October By Investing.com
This article from Investing.com reports on a Form 4 filing for Si-Bone Inc., dated October 11. Form 4 filings are legally required documents submitted to the U.S. Securities and Exchange Commission (SEC) whenever there is a material change in the holdings of company insiders. The article does not provide specific details from the filing but indicates its publication date and the company concerned.
Si-Bone COO & CFO Anshul Maheshwari sells $94,078 in company stock By Investing.com
Anshul Maheshwari, COO and CFO of SI-BONE, Inc. (NASDAQ:SIBN), sold 5,049 shares of company stock for approximately $94,078 in early October 2026. These transactions included "sell to cover" sales for tax obligations and sales made under a 10b5-1 trading plan, with the stock trading above its perceived fair value according to InvestingPro data. The company recently reported strong Q2 2026 financial results, exceeding Wall Street expectations.
Form 4 Si-Bone Inc For: 11 October By Investing.com
This article from Investing.com reports on a Form 4 filing for Si-Bone Inc. The brief news item indicates the filing was made on October 11th. No further details about the content of the Form 4 are provided within the article.
Form 4 Si-Bone Inc For: 6 October By Investing.com
This article reports on a Form 4 filing for Si-Bone Inc. on October 6, highlighting its publication by Investing.com. It indicates that the company's stock symbol is SIBN, which experienced a 2.70% increase. The article provides only this minimal information about the filing.
Si-Bone SVP Michael Pisetsky sells $56,918 in stock
Michael A. Pisetsky, SVP of Operations & Administration and Chief Legal Officer at SI-BONE, Inc. (NASDAQ:SIBN), sold 3,133 shares of company stock totaling $56,918 to cover tax obligations from restricted stock unit vesting. Following these "sell to cover" transactions, which are not discretionary, Mr. Pisetsky still beneficially owns 270,517 shares. The company recently reported strong Q2 2026 results, surpassing Wall Street expectations, with Canaccord Genuity reiterating a Buy rating.
Si-Bone chief op & financial officer sells $94,078 in stock
Anshul Maheshwari, Chief Op & Financial Officer of SI-BONE, Inc. (NASDAQ:SIBN), sold 5,049 shares of company stock totaling $94,078 in early October 2026. These sales included "sell to cover" transactions for tax obligations and shares sold under a pre-established 10b5-1 trading plan. Following these transactions, Mr. Maheshwari beneficially owns 218,235 shares, including restricted stock units.
Tax withholding requires SI-BONE (SIBN) legal chief to sell 3,133 shares
Michael A. Pisetsky, SVP, Ops & Adm/Chief Legal Ofr at SI-BONE (SIBN), sold 3,133 shares of common stock on October 2, 2026. These sales were not discretionary but were required to cover tax withholding obligations related to the vesting of restricted stock units. The transactions involved three sales at weighted average prices of $18.2033, $18.1418, and $18.1400 per share.
Form 4 Si-Bone Inc For: 6 October By Investing.com
This article announces the filing of Form 4 by Si-Bone Inc on October 6, 2026. Form 4 is a document filed with the SEC to report changes in beneficial ownership of a company's securities by officers, directors, and beneficial owners of more than 10% of a class of equity securities. The article provides the title and a timestamp, indicating it is a notice of this filing.
An officer proposes selling 1,731 SI-BONE (NASDAQ: SIBN) shares valued at $31.3K.
Anshul Maheshwari, an officer at SI-BONE, Inc. (NASDAQ: SIBN), has proposed the sale of 1,731 common shares with an aggregate market value of $31,296.48, set for approximately October 5, 2026. This proposed sale is detailed in a Form 144 SEC filing. The filing also reports several prior sales by Maheshwari, including 3,318 shares for $60,376.98 on October 2, 2026, and a 10b5-1 sale of 11,636 shares for $233,971.66 on August 24, 2026.
SI-BONE Officer Anshul Maheshwari Files Form 144 to Sell 1,731 Shares of Common Stock
Anshul Maheshwari, an officer at SI-BONE, INC. (NASDAQ:SIBN), has filed a Form 144 indicating a proposed sale of 1,731 shares of common stock valued at $31,296.48. These shares were acquired via Restricted Stock Units on October 1, 2026, and the sale is planned for October 5, 2026, under a Rule 10b5-1 trading plan. The filing also discloses Maheshwari's previous sales totaling 36,594 shares within the last three months.
Form 4 Si-Bone Inc For: 5 October By Investing.com
This article from Investing.com announces the filing of a Form 4 for Si-Bone Inc. on October 5th. It is a brief news item indicating a regulatory filing has occurred for the company, without providing further details on the content of the filing. The article primarily serves as a placeholder or alert for this corporate action.
Si-Bone director Jeffrey Dunn sells $369,400 in SIBN shares
Jeffrey Dunn, a director at SI-BONE, Inc. (NASDAQ:SIBN), sold 20,000 shares of common stock for $369,400 on October 1, 2026, as part of a pre-arranged trading plan. On the same day, he acquired 20,000 shares through stock option exercises for $93,600. These transactions occurred shortly after SI-BONE reported strong Q2 2026 results, exceeding analyst expectations, yet the stock saw an after-hours decline due to investor concerns about future spending.
After exercising 20,000 options, SI-BONE (SIBN) director Dunn sold 20,000 shares at an average $18.47.
SI-BONE, Inc. director Jeffrey W. Dunn exercised options for 20,000 shares at $4.68 each and subsequently sold these 20,000 common shares at a weighted average price of $18.47 per share on October 1, 2026. The transaction was conducted under a Rule 10b5-1 trading plan established on May 7, 2025. Following these transactions, Dunn holds 66,260 stock options and 16,057 common shares directly, with an additional 81,073 common shares held indirectly through a trust.
SI-BONE stock gets a higher Jefferies target as Onyx expands reach
Jefferies has raised its price target for SI-BONE (SIBN) stock to $25 from $23, following the company's recent FDA clearance for its iFuse Granite Onyx System. This new system addresses screw loosening in spinal fusion and expands SI-BONE's market reach beyond the pelvis. The company reported Q2 2026 revenue of $56.0 million and is focused on converting product expansion into recurring demand, despite a recent voluntary recall of some implants.
SI-BONE clears Onyx as SI-BONE stock sits 17.41% below its high
SI-BONE (SIBN) received FDA 510(k) clearance for its iFuse Granite Onyx System, a product designed for compromised bone in spinal fusion constructs. This clearance targets a significant clinical problem of screw loosening and expands SI-BONE's device platform. The company also reported a 15.17% increase in Q2 2026 revenue to $56.01 million, along with narrower GAAP net losses and positive operating cash flow, while new reimbursement changes are expected to further boost the Granite franchise.
FDA clears a spinal fusion device for people with weak bones. It's SI-BONE's first such product for use beyond the pelvis.
SI-BONE (SIBN) received FDA 510(k) clearance for its iFuse Granite Onyx system, a spinal fusion device designed for use outside the pelvis in patients with compromised bone. This marks the company's first such product for this application and is intended to prevent screw loosening in spinal fusion constructs. Onyx is SI-BONE's third platform to receive FDA Breakthrough Device designation.
SI-Bone (SIBN) Gains FDA Clearance for iFuse Granite Onyx System, Expanding 3D Bone Integration Market
SI-Bone (SIBN) has received FDA 510(k) clearance for its iFuse Granite Onyx System, which expands its 3D-printed bone integration technology beyond the pelvic region to treat compromised bone in other skeletal areas. Despite ongoing losses and negative cash flow, the company has a strong GF Score™ of 85/100, reflecting robust financial health and growth potential. While institutional investors show cautious optimism, consistent insider selling suggests differing perspectives on near-term risks.
SI-BONE Receives FDA 510(k) Clearance for iFuse Granite
SI-BONE, Inc. has received FDA 510(k) clearance for its iFuse Granite Onyx System, marking its first product for compromised bone outside the pelvis. This system is designed to address screw loosening in spinal fusion constructs, especially in patients with low bone density, by promoting rapid osseointegration. The company believes Onyx, designated as a breakthrough device, will expand its market reach and provide better solutions for challenging spinal fusion cases.
SI-Bone stock gains after FDA clears spinal fusion system
SI-Bone Inc. (NASDAQ: SIBN) shares rose after the company announced receiving U.S. FDA 510(k) clearance for its iFuse Granite Onyx System. This system is designed to address screw loosening in spinal fusion procedures, particularly in patients with low bone density, expanding SI-Bone's market beyond its existing pelvic applications. The Onyx system is the company's third platform to be designated as a breakthrough device.
SI-Bone stock gains after FDA clears spinal fusion system
Si-Bone Inc. (NASDAQ:SIBN) shares rose after the company announced FDA 510(k) clearance for its iFuse Granite Onyx System. This new system, designed to address screw loosening in spinal fusion constructs, expands SI-Bone's market beyond pelvic applications to include compromised bone outside the pelvis. The Onyx system is the company's third platform designated as a breakthrough device and is aimed at reducing revision rates in patients with low bone density.
SI-Bone stock gains after FDA clears spinal fusion system
SI-Bone Inc. (NASDAQ:SIBN) shares rose after the company announced it received FDA 510(k) clearance for its iFuse Granite Onyx System. This new system addresses screw loosening in spinal fusion constructs, particularly in patients with low bone density, and expands SI-Bone's market beyond pelvic applications. The Onyx system is the company's third platform designated as a breakthrough device.
SI-BONE, Inc. (SIBN) Investor Outlook: Exploring a 38% Potential Upside in the Healthcare Sector
SI-BONE, Inc. (SIBN) is a medical devices company specializing in innovative orthopedic solutions with notable potential for investors. Analysts have given the company strong buy ratings, forecasting a 38.58% potential upside with an average target price of $25.00. Despite a negative EPS and return on equity, SI-BONE shows promising revenue growth and strategic reinvestment in R&D, positioning it for long-term growth in the healthcare sector.
SI-BONE (NASDAQ: SIBN) Anticipates Up to $150,000 Charge from iFuse TORQ Packaging Recall
SI-BONE (NASDAQ: SIBN) expects a charge of up to $150,000 due to a recall of approximately 3,900 iFuse TORQ implants. The recall was prompted by a packaging defect that posed a potential infection risk, requiring quarantine, repackaging, and re-sterilization. Despite this, the company projects no impact on third-quarter revenue, assuring sufficient inventory for continued supply.
SI-BONE at Morgan Stanley conference: growth broadens beyond pelvis By Investing.com
SI-BONE (SIBN) recently outlined its transformation from a single-disease company to a broader medical technology platform at the Morgan Stanley 24th Annual Global Healthcare Conference. The company reported strong financial results, including 15% worldwide revenue growth and 19% physician base growth in Q2, alongside significant improvements in adjusted EBITDA and positive operating cash flow. SI-BONE is expanding beyond sacroiliac joint dysfunction with new products targeting spine, trauma, and interventional markets, supported by upcoming reimbursement tailwinds and plans for an "innovation super cycle" with regular new product launches.
SI-BONE at Morgan Stanley conference: growth broadens beyond pelvis
SI-BONE (SIBN) presented at the Morgan Stanley 24th Annual Global Healthcare Conference, detailing its evolution from a single-disease company to a broader medical technology platform. The company highlighted strong Q2 2026 revenue growth of 15%, a 19% increase in active physicians, and significant improvements in adjusted EBITDA and operating cash flow. SI-BONE is expanding beyond sacroiliac joint dysfunction with new products like Granite, TNT, iFuse INTRA, and a spinal fusion product, supported by favorable reimbursement changes and an "innovation super cycle" strategy.
SI-BONE (SIBN) director exercises options, sells 20K shares
SI-BONE (SIBN) director Jeffrey W. Dunn exercised options for 20,000 shares at $4.68 per share and subsequently sold all 20,000 shares at a weighted-average price of $18.908 per share on September 1, 2026. These transactions were conducted pursuant to a Rule 10b5-1 trading plan. After the transactions, Dunn holds 16,057 direct shares and 81,073 indirect shares through a living trust.
Si-Bone director Jeffrey Dunn sells $378,160 of common stock
Jeffrey W. Dunn, a director at SI-BONE, Inc. (NASDAQ:SIBN), sold 20,000 shares of company stock for $378,160 on September 1, 2026, following the exercise of stock options. This sale, conducted under a Rule 10b5-1 plan, occurred after a significant 27% return in SIBN stock over six months, though it's noted the stock is trading above its Fair Value. The company recently reported strong Q2 2026 results, exceeding analyst expectations with increased revenue and adjusted loss per share.
Si-Bone director Jeffrey Dunn sells $378,160 of common stock By Investing.com
Jeffrey W. Dunn, a director at SI-BONE, Inc. (NASDAQ:SIBN), sold 20,000 shares of common stock for approximately $378,160 on September 1, 2026, under a Rule 10b5-1 trading plan. This sale followed his exercise of stock options at a lower price. Despite the stock's strong performance, InvestingPro suggests it's trading above its Fair Value, while the company recently exceeded Q2 2026 financial expectations.
SI-BONE To Present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026
SI-BONE, Inc. (Nasdaq: SIBN) announced that it will participate in the 2026 Morgan Stanley 24th Annual Global Healthcare Conference in New York. The company's management will host a fireside chat on Monday, September 14, 2026, at 8:30 a.m. Pacific Time/11:30 a.m. Eastern Time. Interested investors can register to listen to the conference call via webcast on the company's website.
SI-BONE Director Jeffrey Dunn Announces Stock Option Exercises and Sales Under 10b5-1 Plan
SI-BONE, Inc. director Jeffrey W. Dunn exercised stock options and subsequently sold 20,000 shares of common stock on September 1, 2026, under a pre-arranged 10b5-1 trading plan. The shares were acquired at an exercise price of $4.68 each and sold at a weighted-average price of $18.908 per share. After these transactions, Dunn directly holds 16,057 shares and indirectly holds 81,073 shares through a living trust.
SI-BONE To Present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026
SI-BONE, Inc. (Nasdaq: SIBN) announced its participation in the 24th Annual Morgan Stanley Global Healthcare Conference. The company's management will host a fireside chat on September 14, 2026, at 8:30 a.m. Pacific Time/11:30 a.m. Eastern Time. The conference will take place in New York, NY.
Si-Bone (SIBN) is a Great Momentum Stock: Should You Buy?
Si-Bone (SIBN) has been identified as a strong momentum stock with a Zacks Rank of #2 (Buy) and a Momentum Style Score of B. The article highlights its recent positive price performance, outperforming both its industry and the S&P 500 over various periods. Additionally, positive earnings estimate revisions further support its promising outlook for investors seeking near-term growth.
SI-BONE officer plans $232K sale of 11,636 shares | SIBN SEC Filing - Form 144
An officer at SI-BONE, Inc. (SIBN), Anshul Maheshwari, has filed a Form 144 notice to sell 11,636 shares of common stock, valued at approximately $232,254.56, through Morgan Stanley Smith Barney LLC. The sale is planned for on or before August 24, 2026, on NASDAQ. These shares were acquired from the vesting of restricted stock units (RSUs) and performance stock units (PSUs) between January 1, 2025, and February 15, 2026.
SI-BONE (NASDAQ: SIBN) trust to sell 25,972 shares under Rule 144
The DAVID & LAURA FRANCIS JOINT REV TRU/A DTD 01/03/2003, associated with SI-BONE, Inc. (SIBN), has filed to sell 25,972 shares of common stock under Rule 144. These shares were acquired through the vesting of restricted stock units between May 15, 2021, and November 15, 2025. The filing also details prior sales made by the trust and Laura Francis, including significant Rule 10b5-1 transactions in August 2026.
This Insider Has Just Sold Shares In SI-BONE
SI-BONE's CEO & Director, Laura Francis, recently sold US$279k worth of stock at US$18.66 per share, reducing her total holding by 2.8%. This follows a larger sale earlier in the year of US$1.4m worth of shares at a lower price of US$15.44. While insiders own about 3.6% of the company, the consistent selling without any purchases suggests caution for potential investors.
Si-Bone CEO Laura Francis sells over $1 million in company stock
Si-Bone CEO Laura Francis sold over $1 million worth of company stock in transactions occurring on August 20 and 21, 2026, under a pre-arranged trading plan. This sale comes as SI-BONE shares have seen significant gains, though InvestingPro analysis suggests the stock may be overvalued. Despite recent positive financial results and raised guidance, the stock declined after hours due to investor consideration of future outlook and spending plans.
